$ONC News

BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run

BeOne Medicines Inks Voluntary Agreement With U.S. Government To Expand Access To Cancer Drugs For American Patients

BeOne Medicines' Topline Data From Second Interim Analysis of Phase 3 HERIZON-GEA-01 Trial of ZIIHERA (zanidatamab) Plus Chemo, With and Without TEVIMBRA (tislelizumab) Show Statistically Significant and Clinically Meaningful Improvement in Overall Survival Trastuzumab Plus Chemo for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA

BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

BeOne Medicines And Max Foundation Renew Partnership To Expand Access To BRUKINSA For The Treatment Of Chronic Lymphocytic Leukemia Through 2028

Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?

Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook?

TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Aaron Rosenberg Implements A Sell Strategy: Offloads $361K In BeOne Medicines Stock

Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405

BeOne Medicines Q2 Earnings Call Highlights

BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

BeOne Medicines Raises FY2026 Sales Guidance from $6.300B-$6.500B to $6.600B-$6.800B vs $6.479B Est

Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS